Kole Krieger

New Capabilities

Leading commercial strategy for LMN-201

Lumen Bioscience said on October 21 that its oral biologic LMN-201 cured a C. difficile infection and kept it from returning in 83.3% of patients in a placebo-controlled Phase 2 trial, against 36.4% on placebo. Recurrence was 9.1% with the drug and 55.6% with placebo in the 23-patient Part B group.

Updated Oct 26